nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxazosin—CYP2C19—prostate cancer	0.199	1	CbGaD
Doxazosin—ORM1—Abiraterone—prostate cancer	0.112	0.258	CbGbCtD
Doxazosin—CYP2C19—Nilutamide—prostate cancer	0.0367	0.085	CbGbCtD
Doxazosin—CYP2C19—Bicalutamide—prostate cancer	0.0367	0.085	CbGbCtD
Doxazosin—CYP2C19—Flutamide—prostate cancer	0.0304	0.0704	CbGbCtD
Doxazosin—CYP2D6—Bicalutamide—prostate cancer	0.0279	0.0646	CbGbCtD
Doxazosin—ABCB1—Estramustine—prostate cancer	0.0276	0.0638	CbGbCtD
Doxazosin—CYP2D6—Abiraterone—prostate cancer	0.0231	0.0536	CbGbCtD
Doxazosin—ADRA1B—vas deferens—prostate cancer	0.0222	0.385	CbGeAlD
Doxazosin—ABCB1—Cabazitaxel—prostate cancer	0.0182	0.042	CbGbCtD
Doxazosin—ABCB1—Estrone—prostate cancer	0.0178	0.0411	CbGbCtD
Doxazosin—ABCB1—Ethinyl Estradiol—prostate cancer	0.0158	0.0366	CbGbCtD
Doxazosin—CYP2C19—Estradiol—prostate cancer	0.0126	0.0292	CbGbCtD
Doxazosin—ABCB1—Conjugated Estrogens—prostate cancer	0.0116	0.0269	CbGbCtD
Doxazosin—CYP2C19—Prednisone—prostate cancer	0.0109	0.0252	CbGbCtD
Doxazosin—ABCB1—Mitoxantrone—prostate cancer	0.0106	0.0244	CbGbCtD
Doxazosin—ABCB1—Estradiol—prostate cancer	0.0102	0.0236	CbGbCtD
Doxazosin—ABCB1—Prednisone—prostate cancer	0.00877	0.0203	CbGbCtD
Doxazosin—ABCB1—Etoposide—prostate cancer	0.00666	0.0154	CbGbCtD
Doxazosin—ABCB1—Docetaxel—prostate cancer	0.00609	0.0141	CbGbCtD
Doxazosin—ABCB1—Doxorubicin—prostate cancer	0.00454	0.0105	CbGbCtD
Doxazosin—CYP2D6—Doxorubicin—prostate cancer	0.00428	0.0099	CbGbCtD
Doxazosin—KCNH6—prostate gland—prostate cancer	0.0035	0.0607	CbGeAlD
Doxazosin—CYP2C19—urine—prostate cancer	0.00314	0.0545	CbGeAlD
Doxazosin—KCNH6—renal system—prostate cancer	0.00239	0.0414	CbGeAlD
Doxazosin—KCNH7—testis—prostate cancer	0.00217	0.0376	CbGeAlD
Doxazosin—ADRA1D—prostate gland—prostate cancer	0.00194	0.0336	CbGeAlD
Doxazosin—CYP2D6—urine—prostate cancer	0.00183	0.0317	CbGeAlD
Doxazosin—ORM1—prostate gland—prostate cancer	0.0016	0.0277	CbGeAlD
Doxazosin—ADRA1D—epithelium—prostate cancer	0.00143	0.0247	CbGeAlD
Doxazosin—ADRA1B—renal system—prostate cancer	0.00135	0.0234	CbGeAlD
Doxazosin—ADRA1D—urethra—prostate cancer	0.0013	0.0225	CbGeAlD
Doxazosin—Donepezil—ACHE—prostate cancer	0.00124	0.313	CrCbGaD
Doxazosin—ADRA1A—prostate gland—prostate cancer	0.00112	0.0193	CbGeAlD
Doxazosin—KCNH2—prostate gland—prostate cancer	0.00108	0.0187	CbGeAlD
Doxazosin—Prazosin—SLC22A3—prostate cancer	0.000939	0.237	CrCbGaD
Doxazosin—KCNH2—seminal vesicle—prostate cancer	0.000911	0.0158	CbGeAlD
Doxazosin—ADRA2A—prostate gland—prostate cancer	0.000848	0.0147	CbGeAlD
Doxazosin—ORM1—bone marrow—prostate cancer	0.000824	0.0143	CbGeAlD
Doxazosin—ADRA1A—epithelium—prostate cancer	0.000819	0.0142	CbGeAlD
Doxazosin—ADRA1A—renal system—prostate cancer	0.00076	0.0132	CbGeAlD
Doxazosin—KCNH2—renal system—prostate cancer	0.000734	0.0127	CbGeAlD
Doxazosin—KCNH2—urethra—prostate cancer	0.000721	0.0125	CbGeAlD
Doxazosin—ADRA2A—seminal vesicle—prostate cancer	0.000717	0.0124	CbGeAlD
Doxazosin—Prazosin—SLC22A1—prostate cancer	0.000673	0.17	CrCbGaD
Doxazosin—ADRA2A—urethra—prostate cancer	0.000568	0.00984	CbGeAlD
Doxazosin—KCNH2—bone marrow—prostate cancer	0.000555	0.00962	CbGeAlD
Doxazosin—ORM1—lymph node—prostate cancer	0.000511	0.00885	CbGeAlD
Doxazosin—KCNH2—testis—prostate cancer	0.000474	0.00822	CbGeAlD
Doxazosin—ABCB1—prostate gland—prostate cancer	0.000472	0.00819	CbGeAlD
Doxazosin—CYP2D6—renal system—prostate cancer	0.000448	0.00776	CbGeAlD
Doxazosin—ABCB1—seminal vesicle—prostate cancer	0.0004	0.00693	CbGeAlD
Doxazosin—Alfuzosin—CYP3A4—prostate cancer	0.000392	0.0992	CrCbGaD
Doxazosin—ADRA2A—testis—prostate cancer	0.000373	0.00647	CbGeAlD
Doxazosin—Prazosin—CYP1A1—prostate cancer	0.000368	0.0931	CrCbGaD
Doxazosin—ABCB1—epithelium—prostate cancer	0.000347	0.00602	CbGeAlD
Doxazosin—KCNH2—lymph node—prostate cancer	0.000344	0.00596	CbGeAlD
Doxazosin—Donepezil—CYP3A4—prostate cancer	0.000343	0.0867	CrCbGaD
Doxazosin—ABCB1—renal system—prostate cancer	0.000322	0.00558	CbGeAlD
Doxazosin—ABCB1—urethra—prostate cancer	0.000316	0.00548	CbGeAlD
Doxazosin—CYP2D6—testis—prostate cancer	0.000289	0.00501	CbGeAlD
Doxazosin—ADRA2A—lymph node—prostate cancer	0.000271	0.00469	CbGeAlD
Doxazosin—ABCB1—bone marrow—prostate cancer	0.000243	0.00422	CbGeAlD
Doxazosin—ABCB1—testis—prostate cancer	0.000208	0.00361	CbGeAlD
Doxazosin—ABCB1—lymph node—prostate cancer	0.000151	0.00261	CbGeAlD
Doxazosin—Skin disorder—Capecitabine—prostate cancer	3.98e-05	0.000176	CcSEcCtD
Doxazosin—Sweating—Doxorubicin—prostate cancer	3.97e-05	0.000175	CcSEcCtD
Doxazosin—Hyperhidrosis—Capecitabine—prostate cancer	3.96e-05	0.000175	CcSEcCtD
Doxazosin—Hypotension—Docetaxel—prostate cancer	3.95e-05	0.000174	CcSEcCtD
Doxazosin—Haematuria—Doxorubicin—prostate cancer	3.95e-05	0.000174	CcSEcCtD
Doxazosin—Loss of consciousness—Prednisone—prostate cancer	3.93e-05	0.000173	CcSEcCtD
Doxazosin—Epistaxis—Doxorubicin—prostate cancer	3.91e-05	0.000172	CcSEcCtD
Doxazosin—Anorexia—Capecitabine—prostate cancer	3.9e-05	0.000172	CcSEcCtD
Doxazosin—Nausea—Estradiol—prostate cancer	3.9e-05	0.000172	CcSEcCtD
Doxazosin—Vomiting—Mitoxantrone—prostate cancer	3.89e-05	0.000172	CcSEcCtD
Doxazosin—Sinusitis—Doxorubicin—prostate cancer	3.88e-05	0.000171	CcSEcCtD
Doxazosin—Convulsion—Prednisone—prostate cancer	3.87e-05	0.000171	CcSEcCtD
Doxazosin—Visual impairment—Epirubicin—prostate cancer	3.87e-05	0.000171	CcSEcCtD
Doxazosin—Hypertension—Prednisone—prostate cancer	3.86e-05	0.00017	CcSEcCtD
Doxazosin—Rash—Mitoxantrone—prostate cancer	3.86e-05	0.00017	CcSEcCtD
Doxazosin—Dermatitis—Mitoxantrone—prostate cancer	3.86e-05	0.00017	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.85e-05	0.00017	CcSEcCtD
Doxazosin—Headache—Mitoxantrone—prostate cancer	3.83e-05	0.000169	CcSEcCtD
Doxazosin—Hypotension—Capecitabine—prostate cancer	3.83e-05	0.000169	CcSEcCtD
Doxazosin—Insomnia—Docetaxel—prostate cancer	3.83e-05	0.000169	CcSEcCtD
Doxazosin—Arthralgia—Prednisone—prostate cancer	3.81e-05	0.000168	CcSEcCtD
Doxazosin—Myalgia—Prednisone—prostate cancer	3.81e-05	0.000168	CcSEcCtD
Doxazosin—Paraesthesia—Docetaxel—prostate cancer	3.8e-05	0.000168	CcSEcCtD
Doxazosin—Anxiety—Prednisone—prostate cancer	3.79e-05	0.000167	CcSEcCtD
Doxazosin—Bradycardia—Doxorubicin—prostate cancer	3.78e-05	0.000167	CcSEcCtD
Doxazosin—Dyspnoea—Docetaxel—prostate cancer	3.77e-05	0.000166	CcSEcCtD
Doxazosin—Somnolence—Docetaxel—prostate cancer	3.76e-05	0.000166	CcSEcCtD
Doxazosin—Discomfort—Prednisone—prostate cancer	3.76e-05	0.000166	CcSEcCtD
Doxazosin—Eye disorder—Epirubicin—prostate cancer	3.75e-05	0.000166	CcSEcCtD
Doxazosin—Hypersensitivity—Etoposide—prostate cancer	3.75e-05	0.000166	CcSEcCtD
Doxazosin—Tinnitus—Epirubicin—prostate cancer	3.75e-05	0.000165	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.73e-05	0.000165	CcSEcCtD
Doxazosin—Flushing—Epirubicin—prostate cancer	3.73e-05	0.000165	CcSEcCtD
Doxazosin—Rhinitis—Doxorubicin—prostate cancer	3.73e-05	0.000164	CcSEcCtD
Doxazosin—Dyspepsia—Docetaxel—prostate cancer	3.72e-05	0.000164	CcSEcCtD
Doxazosin—Hepatitis—Doxorubicin—prostate cancer	3.72e-05	0.000164	CcSEcCtD
Doxazosin—Insomnia—Capecitabine—prostate cancer	3.7e-05	0.000164	CcSEcCtD
Doxazosin—Hypoaesthesia—Doxorubicin—prostate cancer	3.7e-05	0.000163	CcSEcCtD
Doxazosin—Pharyngitis—Doxorubicin—prostate cancer	3.69e-05	0.000163	CcSEcCtD
Doxazosin—Paraesthesia—Capecitabine—prostate cancer	3.68e-05	0.000162	CcSEcCtD
Doxazosin—Decreased appetite—Docetaxel—prostate cancer	3.68e-05	0.000162	CcSEcCtD
Doxazosin—Asthenia—Etoposide—prostate cancer	3.65e-05	0.000161	CcSEcCtD
Doxazosin—Dyspnoea—Capecitabine—prostate cancer	3.65e-05	0.000161	CcSEcCtD
Doxazosin—Oedema—Prednisone—prostate cancer	3.65e-05	0.000161	CcSEcCtD
Doxazosin—Fatigue—Docetaxel—prostate cancer	3.65e-05	0.000161	CcSEcCtD
Doxazosin—Nausea—Mitoxantrone—prostate cancer	3.64e-05	0.00016	CcSEcCtD
Doxazosin—Infection—Prednisone—prostate cancer	3.62e-05	0.00016	CcSEcCtD
Doxazosin—Constipation—Docetaxel—prostate cancer	3.62e-05	0.00016	CcSEcCtD
Doxazosin—Pain—Docetaxel—prostate cancer	3.62e-05	0.00016	CcSEcCtD
Doxazosin—Dyspepsia—Capecitabine—prostate cancer	3.61e-05	0.000159	CcSEcCtD
Doxazosin—Chills—Epirubicin—prostate cancer	3.6e-05	0.000159	CcSEcCtD
Doxazosin—Pruritus—Etoposide—prostate cancer	3.6e-05	0.000159	CcSEcCtD
Doxazosin—Shock—Prednisone—prostate cancer	3.59e-05	0.000158	CcSEcCtD
Doxazosin—Arrhythmia—Epirubicin—prostate cancer	3.59e-05	0.000158	CcSEcCtD
Doxazosin—Visual impairment—Doxorubicin—prostate cancer	3.58e-05	0.000158	CcSEcCtD
Doxazosin—Tachycardia—Prednisone—prostate cancer	3.56e-05	0.000157	CcSEcCtD
Doxazosin—Decreased appetite—Capecitabine—prostate cancer	3.56e-05	0.000157	CcSEcCtD
Doxazosin—Alopecia—Epirubicin—prostate cancer	3.55e-05	0.000157	CcSEcCtD
Doxazosin—Skin disorder—Prednisone—prostate cancer	3.54e-05	0.000156	CcSEcCtD
Doxazosin—Fatigue—Capecitabine—prostate cancer	3.53e-05	0.000156	CcSEcCtD
Doxazosin—Hyperhidrosis—Prednisone—prostate cancer	3.53e-05	0.000156	CcSEcCtD
Doxazosin—Mental disorder—Epirubicin—prostate cancer	3.52e-05	0.000155	CcSEcCtD
Doxazosin—Pain—Capecitabine—prostate cancer	3.5e-05	0.000155	CcSEcCtD
Doxazosin—Constipation—Capecitabine—prostate cancer	3.5e-05	0.000155	CcSEcCtD
Doxazosin—Malnutrition—Epirubicin—prostate cancer	3.5e-05	0.000154	CcSEcCtD
Doxazosin—Feeling abnormal—Docetaxel—prostate cancer	3.49e-05	0.000154	CcSEcCtD
Doxazosin—Diarrhoea—Etoposide—prostate cancer	3.48e-05	0.000154	CcSEcCtD
Doxazosin—Anorexia—Prednisone—prostate cancer	3.48e-05	0.000153	CcSEcCtD
Doxazosin—Eye disorder—Doxorubicin—prostate cancer	3.47e-05	0.000153	CcSEcCtD
Doxazosin—Tinnitus—Doxorubicin—prostate cancer	3.47e-05	0.000153	CcSEcCtD
Doxazosin—Gastrointestinal pain—Docetaxel—prostate cancer	3.46e-05	0.000153	CcSEcCtD
Doxazosin—Flushing—Doxorubicin—prostate cancer	3.45e-05	0.000152	CcSEcCtD
Doxazosin—Flatulence—Epirubicin—prostate cancer	3.45e-05	0.000152	CcSEcCtD
Doxazosin—Tension—Epirubicin—prostate cancer	3.43e-05	0.000151	CcSEcCtD
Doxazosin—Dysgeusia—Epirubicin—prostate cancer	3.42e-05	0.000151	CcSEcCtD
Doxazosin—Nervousness—Epirubicin—prostate cancer	3.4e-05	0.00015	CcSEcCtD
Doxazosin—Back pain—Epirubicin—prostate cancer	3.38e-05	0.000149	CcSEcCtD
Doxazosin—Feeling abnormal—Capecitabine—prostate cancer	3.38e-05	0.000149	CcSEcCtD
Doxazosin—Dizziness—Etoposide—prostate cancer	3.37e-05	0.000149	CcSEcCtD
Doxazosin—Muscle spasms—Epirubicin—prostate cancer	3.36e-05	0.000148	CcSEcCtD
Doxazosin—Gastrointestinal pain—Capecitabine—prostate cancer	3.35e-05	0.000148	CcSEcCtD
Doxazosin—Abdominal pain—Docetaxel—prostate cancer	3.34e-05	0.000148	CcSEcCtD
Doxazosin—Body temperature increased—Docetaxel—prostate cancer	3.34e-05	0.000148	CcSEcCtD
Doxazosin—Chills—Doxorubicin—prostate cancer	3.33e-05	0.000147	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Prednisone—prostate cancer	3.32e-05	0.000147	CcSEcCtD
Doxazosin—Arrhythmia—Doxorubicin—prostate cancer	3.32e-05	0.000147	CcSEcCtD
Doxazosin—Insomnia—Prednisone—prostate cancer	3.3e-05	0.000146	CcSEcCtD
Doxazosin—Vision blurred—Epirubicin—prostate cancer	3.3e-05	0.000145	CcSEcCtD
Doxazosin—Alopecia—Doxorubicin—prostate cancer	3.28e-05	0.000145	CcSEcCtD
Doxazosin—Paraesthesia—Prednisone—prostate cancer	3.28e-05	0.000145	CcSEcCtD
Doxazosin—Mental disorder—Doxorubicin—prostate cancer	3.26e-05	0.000144	CcSEcCtD
Doxazosin—Urticaria—Capecitabine—prostate cancer	3.25e-05	0.000144	CcSEcCtD
Doxazosin—Ill-defined disorder—Epirubicin—prostate cancer	3.24e-05	0.000143	CcSEcCtD
Doxazosin—Abdominal pain—Capecitabine—prostate cancer	3.24e-05	0.000143	CcSEcCtD
Doxazosin—Body temperature increased—Capecitabine—prostate cancer	3.24e-05	0.000143	CcSEcCtD
Doxazosin—Vomiting—Etoposide—prostate cancer	3.24e-05	0.000143	CcSEcCtD
Doxazosin—Malnutrition—Doxorubicin—prostate cancer	3.24e-05	0.000143	CcSEcCtD
Doxazosin—Agitation—Epirubicin—prostate cancer	3.21e-05	0.000142	CcSEcCtD
Doxazosin—Dyspepsia—Prednisone—prostate cancer	3.21e-05	0.000142	CcSEcCtD
Doxazosin—Rash—Etoposide—prostate cancer	3.21e-05	0.000142	CcSEcCtD
Doxazosin—Dermatitis—Etoposide—prostate cancer	3.21e-05	0.000142	CcSEcCtD
Doxazosin—Headache—Etoposide—prostate cancer	3.19e-05	0.000141	CcSEcCtD
Doxazosin—Flatulence—Doxorubicin—prostate cancer	3.19e-05	0.000141	CcSEcCtD
Doxazosin—Tension—Doxorubicin—prostate cancer	3.17e-05	0.00014	CcSEcCtD
Doxazosin—Decreased appetite—Prednisone—prostate cancer	3.17e-05	0.00014	CcSEcCtD
Doxazosin—Dysgeusia—Doxorubicin—prostate cancer	3.17e-05	0.00014	CcSEcCtD
Doxazosin—Malaise—Epirubicin—prostate cancer	3.15e-05	0.000139	CcSEcCtD
Doxazosin—Fatigue—Prednisone—prostate cancer	3.15e-05	0.000139	CcSEcCtD
Doxazosin—Nervousness—Doxorubicin—prostate cancer	3.14e-05	0.000139	CcSEcCtD
Doxazosin—Vertigo—Epirubicin—prostate cancer	3.14e-05	0.000139	CcSEcCtD
Doxazosin—Syncope—Epirubicin—prostate cancer	3.14e-05	0.000138	CcSEcCtD
Doxazosin—Leukopenia—Epirubicin—prostate cancer	3.13e-05	0.000138	CcSEcCtD
Doxazosin—Back pain—Doxorubicin—prostate cancer	3.13e-05	0.000138	CcSEcCtD
Doxazosin—Constipation—Prednisone—prostate cancer	3.12e-05	0.000138	CcSEcCtD
Doxazosin—Hypersensitivity—Docetaxel—prostate cancer	3.12e-05	0.000138	CcSEcCtD
Doxazosin—Muscle spasms—Doxorubicin—prostate cancer	3.11e-05	0.000137	CcSEcCtD
Doxazosin—Palpitations—Epirubicin—prostate cancer	3.09e-05	0.000136	CcSEcCtD
Doxazosin—Loss of consciousness—Epirubicin—prostate cancer	3.07e-05	0.000136	CcSEcCtD
Doxazosin—Cough—Epirubicin—prostate cancer	3.05e-05	0.000135	CcSEcCtD
Doxazosin—Vision blurred—Doxorubicin—prostate cancer	3.05e-05	0.000135	CcSEcCtD
Doxazosin—Asthenia—Docetaxel—prostate cancer	3.04e-05	0.000134	CcSEcCtD
Doxazosin—Convulsion—Epirubicin—prostate cancer	3.03e-05	0.000134	CcSEcCtD
Doxazosin—Nausea—Etoposide—prostate cancer	3.02e-05	0.000133	CcSEcCtD
Doxazosin—Hypertension—Epirubicin—prostate cancer	3.02e-05	0.000133	CcSEcCtD
Doxazosin—Hypersensitivity—Capecitabine—prostate cancer	3.02e-05	0.000133	CcSEcCtD
Doxazosin—Feeling abnormal—Prednisone—prostate cancer	3.01e-05	0.000133	CcSEcCtD
Doxazosin—Ill-defined disorder—Doxorubicin—prostate cancer	3e-05	0.000132	CcSEcCtD
Doxazosin—Pruritus—Docetaxel—prostate cancer	2.99e-05	0.000132	CcSEcCtD
Doxazosin—Gastrointestinal pain—Prednisone—prostate cancer	2.98e-05	0.000132	CcSEcCtD
Doxazosin—Chest pain—Epirubicin—prostate cancer	2.98e-05	0.000131	CcSEcCtD
Doxazosin—Myalgia—Epirubicin—prostate cancer	2.98e-05	0.000131	CcSEcCtD
Doxazosin—Arthralgia—Epirubicin—prostate cancer	2.98e-05	0.000131	CcSEcCtD
Doxazosin—Agitation—Doxorubicin—prostate cancer	2.97e-05	0.000131	CcSEcCtD
Doxazosin—Anxiety—Epirubicin—prostate cancer	2.97e-05	0.000131	CcSEcCtD
Doxazosin—Discomfort—Epirubicin—prostate cancer	2.94e-05	0.00013	CcSEcCtD
Doxazosin—Asthenia—Capecitabine—prostate cancer	2.94e-05	0.00013	CcSEcCtD
Doxazosin—Malaise—Doxorubicin—prostate cancer	2.92e-05	0.000129	CcSEcCtD
Doxazosin—Dry mouth—Epirubicin—prostate cancer	2.91e-05	0.000128	CcSEcCtD
Doxazosin—Vertigo—Doxorubicin—prostate cancer	2.91e-05	0.000128	CcSEcCtD
Doxazosin—Syncope—Doxorubicin—prostate cancer	2.9e-05	0.000128	CcSEcCtD
Doxazosin—Urticaria—Prednisone—prostate cancer	2.9e-05	0.000128	CcSEcCtD
Doxazosin—Pruritus—Capecitabine—prostate cancer	2.9e-05	0.000128	CcSEcCtD
Doxazosin—Leukopenia—Doxorubicin—prostate cancer	2.9e-05	0.000128	CcSEcCtD
Doxazosin—Diarrhoea—Docetaxel—prostate cancer	2.89e-05	0.000128	CcSEcCtD
Doxazosin—Body temperature increased—Prednisone—prostate cancer	2.88e-05	0.000127	CcSEcCtD
Doxazosin—Abdominal pain—Prednisone—prostate cancer	2.88e-05	0.000127	CcSEcCtD
Doxazosin—Confusional state—Epirubicin—prostate cancer	2.88e-05	0.000127	CcSEcCtD
Doxazosin—Palpitations—Doxorubicin—prostate cancer	2.86e-05	0.000126	CcSEcCtD
Doxazosin—Oedema—Epirubicin—prostate cancer	2.85e-05	0.000126	CcSEcCtD
Doxazosin—Loss of consciousness—Doxorubicin—prostate cancer	2.84e-05	0.000125	CcSEcCtD
Doxazosin—Infection—Epirubicin—prostate cancer	2.84e-05	0.000125	CcSEcCtD
Doxazosin—Cough—Doxorubicin—prostate cancer	2.82e-05	0.000125	CcSEcCtD
Doxazosin—Shock—Epirubicin—prostate cancer	2.81e-05	0.000124	CcSEcCtD
Doxazosin—Convulsion—Doxorubicin—prostate cancer	2.8e-05	0.000124	CcSEcCtD
Doxazosin—Diarrhoea—Capecitabine—prostate cancer	2.8e-05	0.000124	CcSEcCtD
Doxazosin—Dizziness—Docetaxel—prostate cancer	2.8e-05	0.000123	CcSEcCtD
Doxazosin—Thrombocytopenia—Epirubicin—prostate cancer	2.79e-05	0.000123	CcSEcCtD
Doxazosin—Hypertension—Doxorubicin—prostate cancer	2.79e-05	0.000123	CcSEcCtD
Doxazosin—Tachycardia—Epirubicin—prostate cancer	2.79e-05	0.000123	CcSEcCtD
Doxazosin—Skin disorder—Epirubicin—prostate cancer	2.77e-05	0.000122	CcSEcCtD
Doxazosin—Hyperhidrosis—Epirubicin—prostate cancer	2.76e-05	0.000122	CcSEcCtD
Doxazosin—Chest pain—Doxorubicin—prostate cancer	2.75e-05	0.000122	CcSEcCtD
Doxazosin—Myalgia—Doxorubicin—prostate cancer	2.75e-05	0.000122	CcSEcCtD
Doxazosin—Arthralgia—Doxorubicin—prostate cancer	2.75e-05	0.000122	CcSEcCtD
Doxazosin—Anxiety—Doxorubicin—prostate cancer	2.74e-05	0.000121	CcSEcCtD
Doxazosin—Discomfort—Doxorubicin—prostate cancer	2.72e-05	0.00012	CcSEcCtD
Doxazosin—Anorexia—Epirubicin—prostate cancer	2.72e-05	0.00012	CcSEcCtD
Doxazosin—Dizziness—Capecitabine—prostate cancer	2.71e-05	0.00012	CcSEcCtD
Doxazosin—Dry mouth—Doxorubicin—prostate cancer	2.69e-05	0.000119	CcSEcCtD
Doxazosin—Vomiting—Docetaxel—prostate cancer	2.69e-05	0.000119	CcSEcCtD
Doxazosin—Hypersensitivity—Prednisone—prostate cancer	2.69e-05	0.000119	CcSEcCtD
Doxazosin—Rash—Docetaxel—prostate cancer	2.67e-05	0.000118	CcSEcCtD
Doxazosin—Hypotension—Epirubicin—prostate cancer	2.67e-05	0.000118	CcSEcCtD
Doxazosin—Dermatitis—Docetaxel—prostate cancer	2.67e-05	0.000118	CcSEcCtD
Doxazosin—Confusional state—Doxorubicin—prostate cancer	2.66e-05	0.000118	CcSEcCtD
Doxazosin—Headache—Docetaxel—prostate cancer	2.65e-05	0.000117	CcSEcCtD
Doxazosin—Oedema—Doxorubicin—prostate cancer	2.64e-05	0.000117	CcSEcCtD
Doxazosin—Infection—Doxorubicin—prostate cancer	2.62e-05	0.000116	CcSEcCtD
Doxazosin—Asthenia—Prednisone—prostate cancer	2.62e-05	0.000116	CcSEcCtD
Doxazosin—Vomiting—Capecitabine—prostate cancer	2.6e-05	0.000115	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.6e-05	0.000115	CcSEcCtD
Doxazosin—Shock—Doxorubicin—prostate cancer	2.6e-05	0.000115	CcSEcCtD
Doxazosin—Thrombocytopenia—Doxorubicin—prostate cancer	2.59e-05	0.000114	CcSEcCtD
Doxazosin—Rash—Capecitabine—prostate cancer	2.58e-05	0.000114	CcSEcCtD
Doxazosin—Pruritus—Prednisone—prostate cancer	2.58e-05	0.000114	CcSEcCtD
Doxazosin—Insomnia—Epirubicin—prostate cancer	2.58e-05	0.000114	CcSEcCtD
Doxazosin—Dermatitis—Capecitabine—prostate cancer	2.58e-05	0.000114	CcSEcCtD
Doxazosin—Tachycardia—Doxorubicin—prostate cancer	2.58e-05	0.000114	CcSEcCtD
Doxazosin—Headache—Capecitabine—prostate cancer	2.57e-05	0.000113	CcSEcCtD
Doxazosin—Skin disorder—Doxorubicin—prostate cancer	2.56e-05	0.000113	CcSEcCtD
Doxazosin—Paraesthesia—Epirubicin—prostate cancer	2.56e-05	0.000113	CcSEcCtD
Doxazosin—Hyperhidrosis—Doxorubicin—prostate cancer	2.55e-05	0.000113	CcSEcCtD
Doxazosin—Dyspnoea—Epirubicin—prostate cancer	2.54e-05	0.000112	CcSEcCtD
Doxazosin—Somnolence—Epirubicin—prostate cancer	2.54e-05	0.000112	CcSEcCtD
Doxazosin—Anorexia—Doxorubicin—prostate cancer	2.52e-05	0.000111	CcSEcCtD
Doxazosin—Nausea—Docetaxel—prostate cancer	2.51e-05	0.000111	CcSEcCtD
Doxazosin—Dyspepsia—Epirubicin—prostate cancer	2.51e-05	0.000111	CcSEcCtD
Doxazosin—Diarrhoea—Prednisone—prostate cancer	2.5e-05	0.00011	CcSEcCtD
Doxazosin—Decreased appetite—Epirubicin—prostate cancer	2.48e-05	0.000109	CcSEcCtD
Doxazosin—Hypotension—Doxorubicin—prostate cancer	2.47e-05	0.000109	CcSEcCtD
Doxazosin—Fatigue—Epirubicin—prostate cancer	2.46e-05	0.000109	CcSEcCtD
Doxazosin—Constipation—Epirubicin—prostate cancer	2.44e-05	0.000108	CcSEcCtD
Doxazosin—Pain—Epirubicin—prostate cancer	2.44e-05	0.000108	CcSEcCtD
Doxazosin—Nausea—Capecitabine—prostate cancer	2.43e-05	0.000107	CcSEcCtD
Doxazosin—Dizziness—Prednisone—prostate cancer	2.41e-05	0.000106	CcSEcCtD
Doxazosin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.41e-05	0.000106	CcSEcCtD
Doxazosin—Insomnia—Doxorubicin—prostate cancer	2.39e-05	0.000105	CcSEcCtD
Doxazosin—Paraesthesia—Doxorubicin—prostate cancer	2.37e-05	0.000105	CcSEcCtD
Doxazosin—Dyspnoea—Doxorubicin—prostate cancer	2.35e-05	0.000104	CcSEcCtD
Doxazosin—Feeling abnormal—Epirubicin—prostate cancer	2.35e-05	0.000104	CcSEcCtD
Doxazosin—Somnolence—Doxorubicin—prostate cancer	2.35e-05	0.000104	CcSEcCtD
Doxazosin—Gastrointestinal pain—Epirubicin—prostate cancer	2.33e-05	0.000103	CcSEcCtD
Doxazosin—Dyspepsia—Doxorubicin—prostate cancer	2.32e-05	0.000103	CcSEcCtD
Doxazosin—Vomiting—Prednisone—prostate cancer	2.32e-05	0.000102	CcSEcCtD
Doxazosin—Rash—Prednisone—prostate cancer	2.3e-05	0.000102	CcSEcCtD
Doxazosin—Dermatitis—Prednisone—prostate cancer	2.3e-05	0.000101	CcSEcCtD
Doxazosin—Decreased appetite—Doxorubicin—prostate cancer	2.3e-05	0.000101	CcSEcCtD
Doxazosin—Headache—Prednisone—prostate cancer	2.29e-05	0.000101	CcSEcCtD
Doxazosin—Fatigue—Doxorubicin—prostate cancer	2.28e-05	0.0001	CcSEcCtD
Doxazosin—Urticaria—Epirubicin—prostate cancer	2.27e-05	0.0001	CcSEcCtD
Doxazosin—Constipation—Doxorubicin—prostate cancer	2.26e-05	9.97e-05	CcSEcCtD
Doxazosin—Pain—Doxorubicin—prostate cancer	2.26e-05	9.97e-05	CcSEcCtD
Doxazosin—Abdominal pain—Epirubicin—prostate cancer	2.26e-05	9.96e-05	CcSEcCtD
Doxazosin—Body temperature increased—Epirubicin—prostate cancer	2.26e-05	9.96e-05	CcSEcCtD
Doxazosin—Feeling abnormal—Doxorubicin—prostate cancer	2.18e-05	9.6e-05	CcSEcCtD
Doxazosin—Nausea—Prednisone—prostate cancer	2.17e-05	9.57e-05	CcSEcCtD
Doxazosin—Gastrointestinal pain—Doxorubicin—prostate cancer	2.16e-05	9.53e-05	CcSEcCtD
Doxazosin—Hypersensitivity—Epirubicin—prostate cancer	2.1e-05	9.28e-05	CcSEcCtD
Doxazosin—Urticaria—Doxorubicin—prostate cancer	2.1e-05	9.26e-05	CcSEcCtD
Doxazosin—Body temperature increased—Doxorubicin—prostate cancer	2.09e-05	9.21e-05	CcSEcCtD
Doxazosin—Abdominal pain—Doxorubicin—prostate cancer	2.09e-05	9.21e-05	CcSEcCtD
Doxazosin—Asthenia—Epirubicin—prostate cancer	2.05e-05	9.04e-05	CcSEcCtD
Doxazosin—Pruritus—Epirubicin—prostate cancer	2.02e-05	8.91e-05	CcSEcCtD
Doxazosin—Diarrhoea—Epirubicin—prostate cancer	1.95e-05	8.62e-05	CcSEcCtD
Doxazosin—Hypersensitivity—Doxorubicin—prostate cancer	1.95e-05	8.59e-05	CcSEcCtD
Doxazosin—Asthenia—Doxorubicin—prostate cancer	1.89e-05	8.36e-05	CcSEcCtD
Doxazosin—Dizziness—Epirubicin—prostate cancer	1.89e-05	8.33e-05	CcSEcCtD
Doxazosin—Pruritus—Doxorubicin—prostate cancer	1.87e-05	8.24e-05	CcSEcCtD
Doxazosin—Vomiting—Epirubicin—prostate cancer	1.81e-05	8.01e-05	CcSEcCtD
Doxazosin—Diarrhoea—Doxorubicin—prostate cancer	1.81e-05	7.97e-05	CcSEcCtD
Doxazosin—Rash—Epirubicin—prostate cancer	1.8e-05	7.94e-05	CcSEcCtD
Doxazosin—Dermatitis—Epirubicin—prostate cancer	1.8e-05	7.93e-05	CcSEcCtD
Doxazosin—Headache—Epirubicin—prostate cancer	1.79e-05	7.89e-05	CcSEcCtD
Doxazosin—Dizziness—Doxorubicin—prostate cancer	1.75e-05	7.71e-05	CcSEcCtD
Doxazosin—Nausea—Epirubicin—prostate cancer	1.7e-05	7.48e-05	CcSEcCtD
Doxazosin—Vomiting—Doxorubicin—prostate cancer	1.68e-05	7.41e-05	CcSEcCtD
Doxazosin—Rash—Doxorubicin—prostate cancer	1.66e-05	7.35e-05	CcSEcCtD
Doxazosin—Dermatitis—Doxorubicin—prostate cancer	1.66e-05	7.34e-05	CcSEcCtD
Doxazosin—Headache—Doxorubicin—prostate cancer	1.65e-05	7.3e-05	CcSEcCtD
Doxazosin—Nausea—Doxorubicin—prostate cancer	1.57e-05	6.92e-05	CcSEcCtD
Doxazosin—ADRA1B—Signaling Pathways—EGF—prostate cancer	3.71e-06	4.58e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IRS1—prostate cancer	3.71e-06	4.58e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CG—prostate cancer	3.71e-06	4.57e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—LEP—prostate cancer	3.7e-06	4.56e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ITPR1—prostate cancer	3.7e-06	4.56e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—IL2—prostate cancer	3.69e-06	4.56e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—RXRA—prostate cancer	3.69e-06	4.56e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TERT—prostate cancer	3.68e-06	4.54e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CAV1—prostate cancer	3.66e-06	4.52e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—JAK2—prostate cancer	3.65e-06	4.5e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—KDR—prostate cancer	3.62e-06	4.47e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	3.6e-06	4.45e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—TYMS—prostate cancer	3.58e-06	4.42e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—PIK3CA—prostate cancer	3.58e-06	4.42e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MDM2—prostate cancer	3.56e-06	4.4e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—COMT—prostate cancer	3.56e-06	4.39e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—INS—prostate cancer	3.55e-06	4.39e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GSTP1—prostate cancer	3.54e-06	4.37e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—GSTM1—prostate cancer	3.54e-06	4.36e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—ESR1—prostate cancer	3.53e-06	4.35e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	3.52e-06	4.34e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—ERBB2—prostate cancer	3.51e-06	4.34e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—INS—prostate cancer	3.51e-06	4.33e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—TYMS—prostate cancer	3.49e-06	4.31e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Hemostasis—AKT1—prostate cancer	3.49e-06	4.3e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ITPR1—prostate cancer	3.48e-06	4.3e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	3.48e-06	4.3e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—LPL—prostate cancer	3.47e-06	4.28e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PIK3CB—prostate cancer	3.47e-06	4.28e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—GSTM1—prostate cancer	3.45e-06	4.26e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—BAD—prostate cancer	3.44e-06	4.25e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IGF1—prostate cancer	3.44e-06	4.24e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—CREBBP—prostate cancer	3.44e-06	4.24e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—LEP—prostate cancer	3.43e-06	4.24e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	3.42e-06	4.22e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CAV1—prostate cancer	3.4e-06	4.2e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—LPL—prostate cancer	3.39e-06	4.18e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—KDR—prostate cancer	3.36e-06	4.15e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.35e-06	4.14e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	3.34e-06	4.12e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—APC—prostate cancer	3.34e-06	4.12e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	3.33e-06	4.11e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ERCC2—prostate cancer	3.32e-06	4.1e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	3.32e-06	4.1e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	3.3e-06	4.07e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EGF—prostate cancer	3.3e-06	4.07e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IRS1—prostate cancer	3.3e-06	4.07e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—TYMS—prostate cancer	3.29e-06	4.06e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—ESR1—prostate cancer	3.28e-06	4.05e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CYP1A1—prostate cancer	3.27e-06	4.04e-05	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	3.27e-06	4.04e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	3.26e-06	4.03e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CD—prostate cancer	3.26e-06	4.02e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	3.25e-06	4.02e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—GSTM1—prostate cancer	3.25e-06	4.01e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ERCC2—prostate cancer	3.24e-06	4e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	3.23e-06	3.99e-05	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	3.22e-06	3.97e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	3.2e-06	3.95e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—BAD—prostate cancer	3.2e-06	3.95e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—LPL—prostate cancer	3.19e-06	3.94e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CASP3—prostate cancer	3.19e-06	3.94e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IL2—prostate cancer	3.18e-06	3.93e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—IL6—prostate cancer	3.17e-06	3.91e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—FGF2—prostate cancer	3.16e-06	3.9e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—INS—prostate cancer	3.16e-06	3.9e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—MTHFR—prostate cancer	3.12e-06	3.86e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—NOS3—prostate cancer	3.12e-06	3.85e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CCND1—prostate cancer	3.1e-06	3.83e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—APC—prostate cancer	3.1e-06	3.82e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	3.1e-06	3.82e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	3.09e-06	3.82e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.08e-06	3.81e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—NOS3—prostate cancer	3.08e-06	3.8e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	3.07e-06	3.79e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PPARA—prostate cancer	3.07e-06	3.78e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IRS1—prostate cancer	3.06e-06	3.78e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EGF—prostate cancer	3.06e-06	3.78e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ERCC2—prostate cancer	3.06e-06	3.77e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IGF1—prostate cancer	3.05e-06	3.77e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—MTHFR—prostate cancer	3.05e-06	3.76e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	3.04e-06	3.75e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—JAK2—prostate cancer	3.03e-06	3.74e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MMP9—prostate cancer	3.01e-06	3.72e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	3e-06	3.71e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PTEN—prostate cancer	3e-06	3.7e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PPARA—prostate cancer	2.99e-06	3.69e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	2.97e-06	3.67e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	2.97e-06	3.66e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MDM2—prostate cancer	2.96e-06	3.65e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	2.95e-06	3.64e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—INS—prostate cancer	2.93e-06	3.62e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	2.93e-06	3.62e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	2.92e-06	3.61e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	2.92e-06	3.6e-05	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	2.9e-06	3.58e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	2.9e-06	3.58e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CAV1—prostate cancer	2.88e-06	3.56e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	2.88e-06	3.55e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—MTHFR—prostate cancer	2.87e-06	3.55e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	2.87e-06	3.55e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	2.87e-06	3.54e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—EP300—prostate cancer	2.86e-06	3.53e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CB—prostate cancer	2.84e-06	3.5e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IGF1—prostate cancer	2.84e-06	3.5e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	2.82e-06	3.48e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PPARA—prostate cancer	2.82e-06	3.48e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PTGS2—prostate cancer	2.81e-06	3.47e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CAV1—prostate cancer	2.81e-06	3.47e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—FGF2—prostate cancer	2.81e-06	3.46e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—SRC—prostate cancer	2.78e-06	3.43e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—NOS3—prostate cancer	2.77e-06	3.42e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	2.76e-06	3.41e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.75e-06	3.4e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	2.74e-06	3.38e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	2.72e-06	3.36e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	2.71e-06	3.34e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	2.7e-06	3.33e-05	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.7e-06	3.33e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	2.69e-06	3.33e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—JAK2—prostate cancer	2.69e-06	3.32e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—STAT3—prostate cancer	2.68e-06	3.31e-05	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	2.67e-06	3.3e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	2.67e-06	3.29e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CAV1—prostate cancer	2.65e-06	3.27e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CASP3—prostate cancer	2.65e-06	3.27e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IL2—prostate cancer	2.64e-06	3.26e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	2.64e-06	3.25e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—IL6—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MDM2—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.63e-06	3.24e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—FGF2—prostate cancer	2.61e-06	3.22e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	2.59e-06	3.2e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CCND1—prostate cancer	2.58e-06	3.18e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—NOS3—prostate cancer	2.57e-06	3.17e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CG—prostate cancer	2.56e-06	3.16e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	2.56e-06	3.15e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	2.55e-06	3.15e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MMP9—prostate cancer	2.5e-06	3.09e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—JAK2—prostate cancer	2.5e-06	3.09e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	2.49e-06	3.08e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—MYC—prostate cancer	2.49e-06	3.07e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PTEN—prostate cancer	2.49e-06	3.07e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—INS—prostate cancer	2.49e-06	3.07e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	2.48e-06	3.06e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	2.46e-06	3.03e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PTEN—prostate cancer	2.45e-06	3.03e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.45e-06	3.02e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MDM2—prostate cancer	2.44e-06	3.01e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—EGFR—prostate cancer	2.43e-06	3.01e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CREBBP—prostate cancer	2.43e-06	3e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—INS—prostate cancer	2.43e-06	2.99e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	2.43e-06	2.99e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.41e-06	2.98e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	2.41e-06	2.97e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	2.4e-06	2.96e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CREBBP—prostate cancer	2.38e-06	2.93e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EP300—prostate cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CASP3—prostate cancer	2.35e-06	2.9e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IL2—prostate cancer	2.35e-06	2.9e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—EP300—prostate cancer	2.34e-06	2.89e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—IL6—prostate cancer	2.34e-06	2.88e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.31e-06	2.85e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—SRC—prostate cancer	2.31e-06	2.85e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—KRAS—prostate cancer	2.3e-06	2.84e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CCND1—prostate cancer	2.29e-06	2.82e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—INS—prostate cancer	2.29e-06	2.82e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.28e-06	2.82e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	2.27e-06	2.8e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CD—prostate cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	2.25e-06	2.77e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CREBBP—prostate cancer	2.24e-06	2.76e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	2.23e-06	2.75e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—STAT3—prostate cancer	2.22e-06	2.74e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MMP9—prostate cancer	2.22e-06	2.74e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	2.21e-06	2.73e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PTEN—prostate cancer	2.21e-06	2.73e-05	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	2.2e-06	2.72e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CASP3—prostate cancer	2.18e-06	2.7e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IL2—prostate cancer	2.18e-06	2.69e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—NOS3—prostate cancer	2.18e-06	2.69e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—IL6—prostate cancer	2.17e-06	2.68e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	2.15e-06	2.66e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—NOS3—prostate cancer	2.13e-06	2.63e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CCND1—prostate cancer	2.13e-06	2.62e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.12e-06	2.62e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	2.11e-06	2.61e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EP300—prostate cancer	2.11e-06	2.6e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	2.11e-06	2.6e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—MYC—prostate cancer	2.07e-06	2.55e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MMP9—prostate cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	2.06e-06	2.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	2.06e-06	2.54e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PTEN—prostate cancer	2.05e-06	2.53e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—SRC—prostate cancer	2.05e-06	2.53e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—TP53—prostate cancer	2.04e-06	2.52e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EGFR—prostate cancer	2.02e-06	2.49e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CB—prostate cancer	2.01e-06	2.48e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—NOS3—prostate cancer	2e-06	2.47e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	2e-06	2.47e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.99e-06	2.46e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PTGS2—prostate cancer	1.99e-06	2.46e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.97e-06	2.44e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CB—prostate cancer	1.96e-06	2.42e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.96e-06	2.42e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PTGS2—prostate cancer	1.95e-06	2.4e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—KRAS—prostate cancer	1.91e-06	2.36e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.9e-06	2.35e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—IL6—prostate cancer	1.87e-06	2.31e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.85e-06	2.29e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.85e-06	2.28e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.84e-06	2.27e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.83e-06	2.26e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PTGS2—prostate cancer	1.83e-06	2.26e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.83e-06	2.26e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.79e-06	2.22e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	1.75e-06	2.16e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PTEN—prostate cancer	1.74e-06	2.15e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.73e-06	2.14e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—AKT1—prostate cancer	1.73e-06	2.13e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.71e-06	2.1e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.7e-06	2.1e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PTEN—prostate cancer	1.7e-06	2.09e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—TP53—prostate cancer	1.7e-06	2.09e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—KRAS—prostate cancer	1.7e-06	2.09e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.67e-06	2.06e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—EP300—prostate cancer	1.66e-06	2.05e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—EP300—prostate cancer	1.62e-06	2e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PTEN—prostate cancer	1.6e-06	1.97e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.58e-06	1.94e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.56e-06	1.92e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—IL6—prostate cancer	1.55e-06	1.92e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—EP300—prostate cancer	1.52e-06	1.88e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—TP53—prostate cancer	1.51e-06	1.86e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.45e-06	1.79e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—AKT1—prostate cancer	1.43e-06	1.77e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—AKT1—prostate cancer	1.41e-06	1.75e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.4e-06	1.73e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—IL6—prostate cancer	1.38e-06	1.7e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.28e-06	1.58e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—AKT1—prostate cancer	1.27e-06	1.57e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.23e-06	1.51e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—PIK3CA—prostate cancer	1.2e-06	1.48e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.18e-06	1.46e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.13e-06	1.39e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—AKT1—prostate cancer	1e-06	1.24e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—AKT1—prostate cancer	9.78e-07	1.21e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—AKT1—prostate cancer	9.21e-07	1.14e-05	CbGpPWpGaD
